A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

Inclusion criteria: 1. Male or female aged ≥ 18 years at the time of signing the informed consent 2. Express interest to participate in a future CKD clinical study 3. eGFR ≥ 20 to \< 90 mL/min/1.73 m2 (eGFRcr\[AS\], Section 8.2.1) (Delgado et al 2022, Inker et al. 2021) 4. UACR ≥ 700 mg/g or UPCR ≥ 1000 mg/g based on urine sample at time of screening visit 5. Receiving RAS inhibitor therapy (ACEi or ARB) that has been at stable dosing for at least 4 weeks. Exceptions from this requirement will be made for participants who are unable to tolerate RAS inhibitor therapy 6. Provision of signed and dated written informed consent before any study-specific procedures Exclusion criteria: 1. Known NYHA class III or class IV Congestive Heart Failure at the time of enrolment 2. Known T1DM 3. Known history of any life-threatening cardiac dysrhythmia (continuous or paroxysmal) 4. Known history of solid organ transplantation 5. Known history or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2i (eg, dapagliflozin, canagliflozin, empagliflozin) or endothelin receptor antagonists (eg, ambrisentan, atrasentan, bosentan) 6. Known blood-borne diseases such as specified in Appendix B (category A and B) 7. Known pregnancy at the time for the visit or have an intention to become pregnant 8. Lupus nephritis, anti-neutrophil cytoplasmic autoantibody vasculitis, minimal change disease, autosomal dominant polycystic kidney disease (polycystic kidney disease), Alport syndrome, patients on renal replacement therapy, or clinical nephrotic syndrome with problematic oedema